Floatz logo

Empagliflozin

Dumping Syndrome

Insel Gruppe AG, University Hospital BernSmall moleculePhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Dumping Syndrome cohort.

Asset / SponsorPhaseRating
Cabergoline
RECORDATI GROUP
Phase 4BB
Pasireotide
RECORDATI GROUP
Phase 4BB
SOMATOSTATIN
Cambridge University Hospitals NHS Foundation Trust
N/AD
Sulfasalazine
St. James's Hospital, Ireland
UnknownD
Exendin 9-39
Cambridge University Hospitals NHS Foundation Trust
N/AD

View all 9 →

Same molecule, other indications

Empagliflozin is also rated in:

prediabetes syndromeActive
BBB
Indicative · Phase 4
74 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseActive
BBB
Indicative · Phase 4
73 / 100
View asset →
type 2 diabetes mellitusActive
BBB
Indicative · Phase 4
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →